Click on image to view larger version.

Figure 2 (A) Rates of all-cause mortality (D), myocardial infarction (MI), or severe recurrent ischemia leading to urgent revascularization (UR) through 14 days among all patients in Platelet Receptor inhibition for Ischemic Syndrome Management in Patients Limited to very Unstable Signs and Symptoms (PRISM-PLUS) trial, with patients stratified by Thrombolysis In Myocardial Infarction (TIMI) risk score. Adapted from Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non–ST-elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002;23:223–9. (B) Rates of D, MI, or re-admission for acute coronary syndrome (ACS) through 6 months among all patients in Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS) TIMI-18, with patients stratified by TIMI risk score. NSTEMI = non–ST-segment elevation myocardial infarction; % Popl’n = percent of overall trial population with that TIMI Risk Score; UA = unstable angina.